Transgene Announces Financial Calendar for 2026

Core Viewpoint - Transgene, a biotech company specializing in virus-based immunotherapies for cancer treatment, has announced its financial reporting and annual shareholders' meeting dates for 2026 [1]. Financial Reporting Schedule - The company will release its 2025 Fiscal Year Results on March 24, 2026 [1]. - The First Quarter 2026 Financial Results will be announced on April 29, 2026 [1]. - The Annual Shareholders' Meeting is scheduled for May 13, 2026 [1]. - The First Half 2026 Financial Results will be disclosed on September 24, 2026 [1]. - The Third Quarter 2026 Financial Results will be reported on November 9, 2026 [1]. Company Overview - Transgene focuses on designing and developing targeted immunotherapies for cancer, with a portfolio of viral vector-based immunotherapeutics [2]. - The lead asset, TG4050, is the first individualized therapeutic vaccine based on the myvac® platform, showing proof of principle in treating head and neck cancers [2]. - Other assets include BT-001, an oncolytic virus in clinical development, and ongoing innovative discovery and preclinical work for novel immunotherapies [2]. Technological Innovation - The myvac® platform enables precision medicine through a tailored virus-based immunotherapy that incorporates patient-specific mutations identified by Artificial Intelligence in collaboration with NEC [3].